Berger R L, McCormick J R, Stetz J D, Klein M D, Ryan T J, Carr J, Sweet S, Bernhard W F
JAMA. 1980 Jan 4;243(1):46-9.
A paracorporeal left ventricular assist device (LVAD) with a capacity to pump 8 L/min of blood was employed in a clinical trial, and this report details the first survivor. A 60-year-old man could not be separated from the pump oxygenator following coronary artery bypass grafting, and, therefore, an LVAD was employed. Almost the entire left ventricular workload was assumed by the mechanical pump so that the myocardium was allowed to rest and recover. The LVAD support was continued for 105 hours. It provided satisfactory total body perfusion with maintenance of good hemodynamics--without serious deleterious effects on hematologic factors. The patient is alive and active without cardiac symptoms 16 months after his operation. The total experience with 13 LVAD implantations warrants continuation of the clinical trials in selected patients.
一项临床试验采用了一种体外左心室辅助装置(LVAD),其泵血能力为每分钟8升,本报告详细介绍了首例存活者。一名60岁男性在冠状动脉搭桥术后无法脱离体外循环泵氧合器,因此使用了LVAD。机械泵承担了几乎全部的左心室工作负荷,从而使心肌得以休息和恢复。LVAD支持持续了105小时。它提供了令人满意的全身灌注,维持了良好的血流动力学——对血液学因素没有严重的有害影响。该患者术后16个月仍存活且活动自如,无心脏症状。13例LVAD植入的总体经验表明,有必要在选定患者中继续进行临床试验。